BIOGEN MA INC. v. EMD SERONO, INC. , No. 19-1133 (Fed. Cir. 2020)
Annotate this CaseThis opinion or order relates to an opinion or order originally issued on September 28, 2020.
Download PDF
Case: 19-1133 Document: 98 Page: 1 Filed: 11/20/2020 United States Court of Appeals for the Federal Circuit ______________________ November 20, 2020 ERRATA ______________________ Appeal No. 2019-1133 BIOGEN MA INC., Plaintiff -Appellee v. EMD SERONO, INC., PFIZER INC., Defendants-Appellants BAYER HEALTHCARE PHARMACEUTICALS INC., NOVARTIS PHARMACEUTICALS CORPORATION, Defendants Decided: September 28, 2020 Precedential Opinion ______________________ Please make the following changes: On page 8, lines 17–20, change “emphasized that whereas the attached carbohydrate groups in native IFN-β protein were glycosolated, the attached carbohydrate groups in recombinant IFN-β were not glycosolated,” to —explained that the glycosylation patterns in native IFN-β and recombinant IFN-β were different,—.
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
